RSS Feeds
Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force
- Alaa Rostom, MD, MSc;
- Catherine Dubé, MD, MSc;
- Gabriela Lewin, MD;
- Alexander Tsertsvadze, MD, MSc;
- Nicholas Barrowman, PhD;
- Catherine Code, MD;
- Margaret Sampson, MLIS; and
- David Moher, PhD, for the U.S. Preventive Services Task Force
- From University of Calgary, Calgary, Alberta, Canada, and Chalmers Research Group, Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, and Carleton University, Ottawa, Ontario, Canada.
-
View larger version:Figure. Study flow diagram.Studies not shown but included were acetylsalicylic acid (ASA) studies or studies that considered more than 1 intervention, outcome, or both. The Nurses' Health Study (NHS) represents an initial publication (46) and a follow-up publication (34) for colorectal cancer (CRC) and a separate publication for colorectal adenoma (CRA) (47). Three cyclooxygenase (COX)-2 inhibitor polyp studies and a systematic review were added after we submitted our report to the U.S. Preventive Services Task Force and the Agency for Health Research and Quality. *11 of these considered harms of ASA. CV = cardiovascular; NSAID = nonsteroidal anti-inflammatory drug; RCT = randomized, controlled trial.
Related Clinical Content
